EACS2023: 557 Benefits of a change or ART to BIC/FTC/TAF in an HIV clinic in northern Mexico L.G. Castillo , I.D. Cantú Carreon , J.T. Sanchez Beiza , V. Espinoza Ochoa , C.J. Ramirez Salinas , K. Flores Secretaria de Salud del Estado de Nuevo León, Monterrey, Mexico General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Antiretroviral treatment is recommended for all people living with HIV regardless of CD4 cell count and symptomatology, with the aim of reducing progression and HIV transmission. There are multiple reasons why a change can be made in virologic suppressed people when the current regimen is no longer ideal. It is necessary to measure the benefits of a change and to assess its use in Mexican population taking into account viral response and safety and tolerability profiles. Method: An electronic database of CAPASITS in Monterrey, Mexico was used, with data of subjects on their first regimen and undetectable. It includes identification number, file number, age, sex, sexual orientation, residence, treatment, date of diagnosis, date of start of therapy and clinimetry. Data was collected from August 2019 to August 2020 and analyzed by SPSS. Results: 886 met inclusion criteria with 691 male (77%) and 195 female (22%); 100% in virologic control. Previous regimens were EFV/FTC/TDF with 44% and DTG with 45%, the rest was protease inhibitors and non-reverse transcriptase analogs, the median weight was 72 kg with a body mass index of 26, creatinine clearance was normal. The population was reviewed 12 months after the change and 99% continued in virologic control. 93% did not report adverse events, only 7% with mild to moderate effects that did not require discontinuation, the most frequent were headache (24.24%), diarrhea (12.12%), insomnia (9.09%), asthenia (9.09%) and weight gain (7.58%). Body weight and BMI after the change was 75 kg and 26.7 Conclusions: This real world study shows high viral suppression and no drug related discontinuations. The most frequent adverse events were headache and diarrhea. There were no discontinuations due to weight gain or adverse effects. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 1 1 1 131
RkJQdWJsaXNoZXIy Mzc2ODc=